Allurion Technologies' Share Soar Following Weight-Loss Data Results

Dow Jones

May 14, 2025

By Stephen Nakrosis

Shares of Allurion Technologies rallied after the company said patients lost weight and maintained muscle mass while using its Allurion Balloon and AI-Powered Virtual Care Suite.

The stock rose 42% to $3.36 in post-market trading on Tuesday, with 3 million shares changing hands. Shares touched a 52-week low of $2.15 on Monday, and have plummeted 96% in the past year.

Allurion said the data was included in four abstracts presented at the European Congress on Obesity, which showed that the company's products aided weight loss with and without the use of GLP-1s.

Data from one abstract indicated potential benefits from using the company's swallowable Procedureless intragastric balloon and Virtual Care Suite with normal dosing of GLP-1s, which built upon previous data.

GLP-1s used in combination with the Virtual Care Suite led to an average gain in lean body mass of 6.1%, the company said. Data was also presented showing that Allurion Balloon used in combination with GLP-1s leads to an average reduction in body weight of 21.2%.

The Allurion Program, which involved 2,000 patients treated between 2017 and 2024, showed an average 12.4% reduction in body weight after four months, and an average increase in muscle mass of 9.8% after six months.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

May 13, 2025 18:04 ET (22:04 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535035669"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535035669\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535035669?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 06:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535035669","market":"fut","top_or_hot":-1,"title":"Allurion Technologies' Share Soar Following Weight-Loss Data Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Allurion Technologies rallied after the company said patients lost weight and maintained muscle mass while using its Allurion Balloon and AI-Powered Virtual Care Suite. \n</p>\n<p>\n  The stock rose 42% to $3.36 in post-market trading on Tuesday, with 3 million shares changing hands. Shares touched a 52-week low of $2.15 on Monday, and have plummeted 96% in the past year. \n</p>\n<p>\n  Allurion said the data was included in four abstracts presented at the European Congress on Obesity, which showed that the company's products aided weight loss with and without the use of GLP-1s. \n</p>\n<p>\n  Data from one abstract indicated potential benefits from using the company's swallowable Procedureless intragastric balloon and Virtual Care Suite with normal dosing of GLP-1s, which built upon previous data. \n</p>\n<p>\n  GLP-1s used in combination with the Virtual Care Suite led to an average gain in lean body mass of 6.1%, the company said. Data was also presented showing that Allurion Balloon used in combination with GLP-1s leads to an average reduction in body weight of 21.2%. \n</p>\n<p>\n  The Allurion Program, which involved 2,000 patients treated between 2017 and 2024, showed an average 12.4%  reduction in body weight after four months, and an average increase in muscle mass of 9.8% after six months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2025 18:04 ET (22:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allurion Technologies' Share Soar Following Weight-Loss Data Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllurion Technologies' Share Soar Following Weight-Loss Data Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-14 06:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Allurion Technologies rallied after the company said patients lost weight and maintained muscle mass while using its Allurion Balloon and AI-Powered Virtual Care Suite. \n</p>\n<p>\n  The stock rose 42% to $3.36 in post-market trading on Tuesday, with 3 million shares changing hands. Shares touched a 52-week low of $2.15 on Monday, and have plummeted 96% in the past year. \n</p>\n<p>\n  Allurion said the data was included in four abstracts presented at the European Congress on Obesity, which showed that the company's products aided weight loss with and without the use of GLP-1s. \n</p>\n<p>\n  Data from one abstract indicated potential benefits from using the company's swallowable Procedureless intragastric balloon and Virtual Care Suite with normal dosing of GLP-1s, which built upon previous data. \n</p>\n<p>\n  GLP-1s used in combination with the Virtual Care Suite led to an average gain in lean body mass of 6.1%, the company said. Data was also presented showing that Allurion Balloon used in combination with GLP-1s leads to an average reduction in body weight of 21.2%. \n</p>\n<p>\n  The Allurion Program, which involved 2,000 patients treated between 2017 and 2024, showed an average 12.4%  reduction in body weight after four months, and an average increase in muscle mass of 9.8% after six months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2025 18:04 ET (22:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALUR","symbol_name":"ALLURION TECHNOLOGIES","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2535035669","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535035669","pubTimestamp":1747173840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Allurion Technologies rallied after the company said patients lost weight and maintained muscle mass while using its Allurion Balloon and AI-Powered Virtual Care Suite.The stock rose 42% to $3.36 in post-market trading on Tuesday, with 3 million shares changing hands. Shares touched a 52-week low of $2.15 on Monday, and have plummeted 96% in the past year.Allurion said the data was included in four abstracts presented at the European Congress on Obesity, which showed that the company's products aided weight loss with and without the use of GLP-1s.Data from one abstract indicated potential benefits from using the company's swallowable Procedureless intragastric balloon and Virtual Care Suite with normal dosing of GLP-1s, which built upon previous data.GLP-1s used in combination with the Virtual Care Suite led to an average gain in lean body mass of 6.1%, the company said. Data was also presented showing that Allurion Balloon used in combination with GLP-1s leads to an average ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALUR":"ALLURION TECHNOLOGIES","BK4192":"特殊消费者服务"},"translate_title":"减肥数据公布后Allurion Technologies股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALUR":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Shares of Allurion Technologies rallied after the company said patients lost weight and maintained muscle mass while using its Allurion Balloon and AI-Powered Virtual Care Suite. \n\n\n  The stock rose 42% to $3.36 in post-market trading on Tuesday, with 3 million shares changing hands. Shares touched a 52-week low of $2.15 on Monday, and have plummeted 96% in the past year. \n\n\n  Allurion said the data was included in four abstracts presented at the European Congress on Obesity, which showed that the company's products aided weight loss with and without the use of GLP-1s. \n\n\n  Data from one abstract indicated potential benefits from using the company's swallowable Procedureless intragastric balloon and Virtual Care Suite with normal dosing of GLP-1s, which built upon previous data. \n\n\n  GLP-1s used in combination with the Virtual Care Suite led to an average gain in lean body mass of 6.1%, the company said. Data was also presented showing that Allurion Balloon used in combination with GLP-1s leads to an average reduction in body weight of 21.2%. \n\n\n  The Allurion Program, which involved 2,000 patients treated between 2017 and 2024, showed an average 12.4%  reduction in body weight after four months, and an average increase in muscle mass of 9.8% after six months. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2025 18:04 ET (22:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}